Physician profile
Jason E Knuffman
NPI 1184690109
$1,251.04
in general payments reported to CMS, 2019-2025
14 companies · $502 in 2025
The $502 reported for 2025 was less than what a typical Allergy & Immunology (Internal Medicine) provider received nationally (typical 2025 total: $681).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50.08 · 2021: $106 · 2022: $84.72 · 2023: $128 · 2024: $381 · 2025: $502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $937 · Education: $72.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $937.45 |
| Education | $72.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $298.48 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $209.97 | 2019-2025 | Airsupra, Tezspire |
| Regeneron Healthcare Solutions, INC. | $176.11 | 2022-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $103.26 | 2025 | |
| Genzyme Corporation | $98.01 | 2023-2025 | |
| Ars Pharmaceuticals Operations, INC. | $69.19 | 2025 | Neffy |
| Sanofi-Aventis U.S. LLC | $57.48 | 2024 | |
| Abbvie INC. | $54.74 | 2022-2025 | |
| Csl Behring | $53.15 | 2024 | Hizentra |
| Pfizer INC. | $41.79 | 2024-2025 | |
| Lilly USA, LLC | $24.60 | 2025 | Ebglyss |
| Welch Allyn | $24.38 | 2021 | |
| Optinose US, INC. | $20.16 | 2022 | |
| Genentech USA, INC. | $19.72 | 2025 | Xolair |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Knuffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.